<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Pharma — Marts 2026]]></title><description><![CDATA[<p dir="auto">Test</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400908/pharma-marts-2026</link><generator>RSS for Node</generator><lastBuildDate>Sun, 07 Jun 2026 15:21:06 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400908.rss" rel="self" type="application/rss+xml"/><pubDate>Mon, 23 Mar 2026 06:07:40 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Pharma — Marts 2026 on Mon, 23 Mar 2026 06:09:16 GMT]]></title><description><![CDATA[<p dir="auto">Lundbecks topchef, Charl Van Zyl, kritiserer Europas bureaukratiske system og manglende incitamenter for innovation, som hæmmer medicinalindustriens vækst. I interviewet med Finans fremhæver Van Zyl derudover, at selskabet fremover vil fokusere på USA og Kina, hvor rammerne for investeringer og innovation er stærkere, mens Europa risikerer at tabe terræn.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/8038367</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8038367</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Mon, 23 Mar 2026 06:09:16 GMT</pubDate></item></channel></rss>